5AM Venture Management LLC Has $5.33 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. $ZNTL

5AM Venture Management LLC raised its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 705.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,947,913 shares of the company’s stock after buying an additional 3,457,913 shares during the quarter. Zentalis Pharmaceuticals makes up about 1.7% of 5AM Venture Management LLC’s holdings, making the stock its 19th largest position. 5AM Venture Management LLC owned 0.05% of Zentalis Pharmaceuticals worth $5,330,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ZNTL. Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $27,000. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at $37,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $41,000. Algert Global LLC bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $73,000. Finally, Barr E S & Co. lifted its stake in shares of Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after buying an additional 17,500 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $3.62 on Thursday. The company’s 50-day moving average is $4.07 and its 200 day moving average is $2.90. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $6.95. The firm has a market capitalization of $257.71 million, a P/E ratio of -2.09 and a beta of 1.96.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -1.92 earnings per share for the current year.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent research reports. Guggenheim raised their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $5.83.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.